Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Objective, but not subjective, EDS was associated with insulin resistance and disordered glucose metabolism among patients with OSA.

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India: Our Bureau, Mumbai Thursday, December 12, 2024, 17:30 Hrs [IST] MannKind Corporation, a company focu ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Shares of firms like Jubilant FoodWorks, Maruti Suzuki, Swiggy, SBI, Vedanta, and others will be in focus on Thursday's trade ...

Greaves Cotton board approved OFS of certain shares of arm Greaves Electric held by the company in the proposed IPO.

Cipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for managing type 1 and type 2 ...

U.K. researchers at Nottingham Trent University, the University of Southampton and University Hospital Southampton and ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the ...